Finance

Lists
Q1 2027 earnings • released • EPS beat +1.78% • Revenue miss -1.12%
See results
SUNPHARMA:NSE
Sun Pharmaceutical Industries Ltd
₹1,954.80
-1.79%
(-35.70) 1D
Aug 3, 2:07:25 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for SUNPHARMA...
Open
₹1,983.20
High
₹1,988.00
Low
₹1,937.00
Mkt. cap
4.69T
Avg. vol.
2.24M
Volume
2.79M
Dividend
0.82%
Quarterly dividend
₹4.00
Ex-dividend date
Jul 7, 2026
P/E ratio
38.75
52-wk high
₹2,046.90
52-wk low
₹1,548.00
EPS
₹50.44
Shares outstanding
0.00
No. of employees
47K
Open
₹1,983.20
High
₹1,988.00
Low
₹1,937.00
Mkt. cap
4.69T
Avg. vol.
2.24M
Volume
2.79M
Dividend
0.82%
Quarterly dividend
₹4.00
Ex-dividend date
Jul 7, 2026
P/E ratio
38.75
52-wk high
₹2,046.90
52-wk low
₹1,548.00
EPS
₹50.44
Shares outstanding
0.00
No. of employees
47K
News stories
From sources across the web
Profile
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. Around 70% of Sun Pharma’s revenue is generated from international markets. The US and India are the largest markets, accounting for over 60% of the company's turnover. Manufacturing is across 43 locations in India, the US, Asia, Africa, Australia and Europe. The products cater to therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its active pharmaceutical products include baricitinib, brivaracetam, and dapaglifozin. Wikipedia
About Sun Pharmaceutical Industries Ltd
CEO-
Employees47K
Founded1983
HeadquartersGoregaon East, Mumbai, India
SectorPharmaceutical industry
Websitesunpharma.com
Last report
Jul 31, 2026
Fiscal period
Q1 2027
EPS / Est. (INR)
₹12.71 / ₹12.48
+1.78%beat
Revenue / Est. (INR)
153.00B / 154.74B
-1.12%miss
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
144.78B
155.21B
146.12B
153.00B
Cost of goods sold
29.83B
29.45B
37.36B
-
Cost of revenue
29.83B
29.45B
37.36B
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27.65B
28.92B
30.60B
-
Operating expense
81.28B
85.13B
80.66B
-
Total operating expenses
111.11B
114.58B
118.02B
-
Operating income
33.67B
40.62B
28.10B
-
Other non operating income
4.70B
5.79B
-14.29B
-
EBT including unusual items
41.55B
42.07B
35.37B
-
EBT excluding unusual items
41.55B
46.97B
26.83B
-
Income tax expense
10.31B
8.26B
8.28B
-
Effective tax rate
24.80%
19.63%
23.40%
-
Other operating expenses
46.34B
48.89B
42.30B
-
Net income
31.18B
33.69B
27.14B
-
Net profit margin
21.54%
21.71%
18.57%
18.92%
Earnings per share
13.00
15.48
11.30
12.71
Interest and investment income
-
-
9.74B
-
Interest expense
-998.60M
-783.60M
-858.90M
-
Net interest expenses
-998.60M
-783.60M
8.89B
-
Depreciation and amortization charges
7.30B
7.32B
7.75B
-
EBITDA
40.82B
46.53B
34.86B
-
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps